VERA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -1.51%, SMA50 -8.96%, SMA200 35.92%). The stock’s 14-day RSI is 45.0 (neutral), while the ATR of 2.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.44% below its high and over 128.55% above its low. Average 10-day trading volume of 883.54 thousand shares is below the 3-month average of 1.14 million, indicating normal recent market interest.

Vera Therapeutics, Inc. generated EPS of -$3.99 over the past year. Five-year average earnings growth is 4.49%. Wall Street analysts project EPS growth of 2.47% annually over the next five years. The latest quarter delivered EPS of -$1.69. The next quarter is forecast at -$1.28. Next year's EPS is expected at -$1.12. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $110.00 to $33.00. The high target offers 226.7% upside. The low target suggests -1.99% downside. The mean target is $76.54. This offers 127.32% upside. Vera Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 27.22%. The prior quarter beat by 3.73%. Over the last six quarters, Apple has recorded several small beats. These include -13.25% in February 26, 2025.

Vera Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.32. This means the shares are trading above this model’s fair value.

Vera Therapeutics, Inc. (NASDAQ:VERA) closed at $33.67 USD, losing -$0.57 (-1.66%) from the previous close of $34.24. The stock is currently mid-range between its 52-week high and low $19.07 and $56.05. With a market capitalization of about $2.42 billion, Vera Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 1.15 million shares, in line with its 52-week average. Headquartered in Brisbane, CA, Vera Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gary Barrera, the company employs approximately 152 people and listed since May 14, 2021. Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States.

Vera Therapeutics, Inc. has 63.82 million shares outstanding. The public float is 42.92 million shares, elevated short interest at 15.31% of float. This equals 8.48 million shares. The short ratio is 5.0 days. Institutional investors hold 116.28% of the float. Insiders own 0.9%. COMMODORE CAPITAL LP holds 4.40 million shares, Sofinnova Venture Partners X, L.P. has 3.47 million shares and Carlyle Genesis UK LLC has 2.96 million shares. Over the past six months, insider transactions show net selling. They sold 38.67 thousand shares across 9 transactions.

Vera Therapeutics, Inc. trades at a P/E ratio of -6.54, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.83 trading at moderately above to book value. The P/FCF stands at -8.24, also below market averages.

Our AI price prediction model suggests that Vera Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.81%, with price expected at $32.05 by June 29, 2026, within a range of $30.33 to $33.59 3-Month Outlook: Projected fall of -31.87%, reaching $22.94 by September 11, 2026, with a range of $20.90 to $24.40. 1-Year Outlook: Projected gain of 22.81%, with price at $41.35 by June 15, 2027, within a range of $37.76 to $45.14.

Vera Therapeutics, Inc. (NASDAQ:VERA) shares are down -11.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vera Therapeutics, Inc. trading at a premium to the broader market with a P/E of -6.54. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $59.71, suggesting 77.34% upside. Our AI forecast model points to short-term weakness (-4.81% over two weeks), a medium-term fall (-31.87% over three months), and a longer-term gain (22.81% over one year), with expected trading ranges indicating moderate volatility.